Afya Limited

Análisis de la acción Afya Limited (AFYA)

$14.530

+0.010 (+0.07%)Al cierre

Loading chart…
Máximo
14.670
Apertura
14.520
Precio medio ponderado por volumen
14.54
Volumen
194.16K
Capitalización
1.53B
Mínimo
14.420
Importe
2.82M
EV/EBITDA, TTM
2.02

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.

ir.afya.com.br

Análisis de IA of Afya Limited (AFYA)

Comprar

Afya Ltd is a good buy right now due to its strong revenue growth, with Q1 2026 revenue reaching BRL 1.012 billion, a 7% year-over-year increase, and a low forward P/E of 7.86, indicating potential undervaluation. However, the main risk is the significant insider selling, which increased by 1215.03% over the last month, suggesting potential concerns about the company's future performance.

Métricas de valoración

El PER previsto actual de Afya Limited (AFYA) es 7.86, frente a su media de 5 años de 10.93.

PER previsto

Infravalorado
Media 5A P/E
10.93
P/E actual
7.86
Sobrevalorada
13.61
Infravalorada
8.25

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
6.35
EV/EBITDA actual
2.02
Sobrevalorada
8.56
Infravalorada
4.13

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
2.08
P/S actual
0.30
Sobrevalorada
2.95
Infravalorada
1.20

Escenarios de precio de Alphio AI para AFYA

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%AFYA

$28.55

Precio del escenario

B

Base

Base · 50%AFYA

$24.23

Precio del escenario

B

Bajista

Bajista · 25%AFYA

$20.66

Precio del escenario

Ballenas con AFYA en cartera

S

SoftBank Group Corp.

+ Con en carteraAFYA

-15.12%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-24 (ET)

10:00:00

Afya and Yduqs Discuss Potential Business Combination

2025-11-12 (ET)

18:14:48

Afya announces Q3 adjusted EBITDA of R$398.9M, a 14.6% increase year-over-year

2025-11-07 (ET)

08:54:49

Afya Reveals Expansion of Medical Seats at ITPAC Porto Nacional

Noticias

Preguntas frecuentes sobre AFYA, respondidas por Alphio AI

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform. It operates in the Academic & Educational Services sector.

Afya Ltd is a good buy right now due to its strong revenue growth, with Q1 2026 revenue reaching BRL 1.012 billion, a 7% year-over-year increase, and a low forward P/E of 7.86, indicating potential undervaluation. However, the main risk is the significant insider selling, which increased by 1215.03% over the last month, suggesting potential concerns about the company's future performance.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar